Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy [Rapid Communications]

Conclusion During the first year, most patients on exemestane plus triptorelin had E2 levels below the defined threshold of 2.72 pg/mL, consistent with levels reported in postmenopausal patients on aromatase inhibitors, but at each time point, at least 17% of patients had levels greater than the threshold.

http://jco.ascopubs.org/cgi/content/short/34/14/1584?rss=1

Source: Journal of Clinical Oncology - May 2, 2016 Category: Cancer & Oncology Authors: Bellet, Gray, Francis, Lang, Ciruelos, Lluch, Climent, Catalan, Avella, Bohn, Gonzalez-Martin, Ferrer, Catalan, Azaro, Rajasekaran, Morales, Vazquez, Fleming, Price, Regan Tags: Hormonal Therapy, Rapid Communications Source Type: research